Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer by unknown
RESEARCH ARTICLE Open Access
Prolactin-induced protein mediates cell invasion
and regulates integrin signaling in estrogen
receptor-negative breast cancer
Ali Naderi* and Michelle Meyer
Abstract
Introduction: Molecular apocrine is a subtype of estrogen receptor (ER)-negative breast cancer that is
characterized by a steroid-response gene signature. We have recently identified a positive feedback loop between
androgen receptor (AR) and extracellular signal-regulated kinase (ERK) signaling in this subtype. In this study, we
investigated the transcriptional regulation of molecular apocrine genes by the AR-ERK feedback loop.
Methods: The transcriptional effects of AR and ERK inhibition on molecular apocrine genes were assessed in cell
lines. The most regulated gene in this process, prolactin-induced protein (PIP), was further studied using
immunohistochemistry of breast tumors and xenograft models. The transcriptional regulation of PIP was assessed
by luciferase reporter assay and chromatin immunoprecipitation. The functional significance of PIP in cell invasion
and viability was assessed using siRNA knockdown experiments and the mechanism of PIP effect on integrin-b1
signaling was studied using immunoblotting and immunoprecipitation.
Results: We found that PIP is the most regulated molecular apocrine gene by the AR-ERK feedback loop and is
overexpressed in ER-/AR+ breast tumors. In addition, PIP expression is regulated by AR-ERK signaling in xenograft
models. These observations are explained by the fact that PIP is a target gene of the ERK-CREB1 pathway and is
also induced by AR activation. Furthermore, we demonstrated that PIP has a significant functional role in
maintaining cell invasion and viability of molecular apocrine cells because of a positive regulatory effect on the
Integrin-ERK and Integrin-Akt signaling pathways. In fact, PIP-knockdown markedly decreases the phosphorylation
of ERK, Akt, and CREB1. Importantly, PIP knockdown leads to a marked reduction of integrin-b1 binding to ILK1 and
ErbB2 that can be reversed by the addition of fibronectin fragments.
Conclusions: We have identified a novel feedback loop between PIP and CREB1 mediated through the Integrin
signaling pathway. In this process, PIP cleaves fibronectin to release fragments that activate integrin signaling,
which in turn increases PIP expression through the ERK-CREB1 pathway. In addition, we demonstrated that PIP
expression has a profound effect on cell invasion and the viability of molecular apocrine cells. Therefore, PIP
signaling may be a potential therapeutic target in molecular apocrine breast cancer.
Introduction
Estrogen receptor-negative (ER-) breast cancer is a hetero-
geneous disease that is characterized by an earlier time-to-
relapse compared to ER+ breast tumors [1,2]. As opposed
to ER+ breast cancer, where the estrogen receptor signal-
ing has a critical biological and therapeutic role, there is
limited knowledge available regarding the pathophysiology
of ER- disease. Therefore, in order to discover effective
therapeutic strategies in ER- breast cancer there is a need
for better understanding of the biology of this disease.
ER- breast cancer can be divided into different molecu-
lar subgroups based on the expression microarray profil-
ing [2-4]. The two most prominent ER- subgroups
include molecular apocrine and basal subtypes [2-4]. The
molecular apocrine subtype is characterized by a steroid-
response gene signature that includes androgen receptor
(AR), FOXA1, TFF3, and a high frequency of ErbB2 over-
expression [3-5]. It is notable that AR expression is
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present in 40% to 50% of ER- breast tumors and the
majority of these cases also have ErbB2 overexpression
[2,6-8]. Furthermore, it has been suggested that a loss of
PTEN at early stages of tumorigenesis predisposes to the
formation of breast tumors with molecular apocrine fea-
tures [9].
Over the past few years, several functional and genomic
studies have signified the importance of AR and ErbB2 sig-
naling in the biology of molecular apocrine breast cancer
[2,5,10-13]. Notably, a recent meta-analysis study has
revealed that AR and ErbB2 signaling are two major acti-
vated pathways in the molecular apocrine subtype [2]. In
addition, we have previously demonstrated a functional
cross-talk between the AR and ErbB2 signaling in molecu-
lar apocrine cells that modulates cell proliferation and
expression of steroid-response genes [10]. Furthermore,
other studies have shown that AR mediates ligand-depen-
dent activation of the Wnt and ErbB2 signaling pathways
through direct transcriptional induction of WNT7B and
ErbB3 [12]. Importantly, AR signaling is a potential thera-
peutic target in ER-/AR+ breast cancer and is currently
under investigation in a clinical trial (ClinicalTrials.gov
Identifier: NCT00468715), [12,14-16].
To delineate the key signaling pathways involved in the
biology of molecular apocrine breast cancer, we have
recently identified a positive feedback loop between the
AR and extracellular signal-regulated kinase (ERK) signal-
ing pathways in this disease [11]. We have shown that in
this feedback loop AR regulates ERK phosphorylation
through the mediation of ErbB2 and, in turn, ERK-CREB1
signaling regulates the transcription of AR in molecular
apocrine cells [11]. This feedback loop provides a molecu-
lar basis for the association between AR expression and
the high prevalence of ErbB2 overexpression in molecular
apocrine tumors [11]. In addition, it explains the mechan-
ism for a synergistic response to the combination of AR
and MEK inhibitors in molecular apocrine models [15].
Although published data support a significant biological
role for the AR and ErbB2 signaling in molecular apocrine
breast cancer, there is currently limited information
regarding other functionally important genes and path-
ways in this disease.
In this study, we investigated the transcriptional regula-
tion of top ranking genes in the molecular apocrine sig-
nature by the AR-ERK feedback loop. We discovered that
Prolactin-Induced Protein (PIP) is highly regulated by
this feedback loop. Importantly, we demonstrated that
PIP is a key mediator of cell invasion and regulates integ-
rin signaling in molecular apocrine cells.
Materials and methods
Cell culture and treatments
Breast cancer cell lines MDA-MB-453, HCC-1954, and
MCF-7 were obtained from American Type Culture
Collection (Manassas, VA, USA). All the culture media
were obtained from Invitrogen (Melbourne, VIC,
Australia). MDA-MB-453 and HCC-1954 cell lines were
cultured in L15 medium, 10% fetal bovine serum (FBS)
and RPMI 1640 medium, 10% FBS, respectively. The
MCF-7 cell line was cultured in (D)MEM/F12 medium,
10% FBS. Cell cultures were carried out in a humidified
37°C incubator supplied with 5% CO2.
The following treatments were applied for the
cell culture experiments: 1) AR inhibitor, flutamide
(Sigma-Aldrich, Sydney, NSW, Australia) at 25 µM to
40 µM concentrations [11]; 2) MEK inhibitor, CI-1040
(PD184352), (Selleck Chemicals, Houston, TX, USA) at
2 µM to 10 µM concentrations [11]; and 3) 5a-andro-
stan-17b-ol-3-one (dihydrotestosterone (DHT)),
(Sigma-Aldrich) at 100 nM concentration [11,17].
Treatments with the inhibitors were performed in
media containing FBS. DHT treatment was carried out
in phenol red-free media (Invitrogen) with 10% Char-
coal/Dextran treated serum (Thermo Scientific,
Melbourne, VIC, Australia) and cell lines were cultured
in the media for 48 hours prior to DHT treatment.
Quantitative real-time polymerase chain reaction
Total RNA extraction was performed as described
before [18]. Quantitative real-time PCR (qPCR) to assess
the expression levels of PIP (assay ID: Hs00160082_m1),
dual specificity phosphatase 6 (DUSP6, assay ID:
Hs00737962_m1), S100A8 (assay ID: Hs00374264_g1),
FOXA1 (assay ID: Hs00270129_m1), transcription
factor AP2B (TFAP2, assay ID: Hs00231468_m1),
SOX11 (assay ID: Hs00846583_s1), BANP (assay ID:
Hs00215370_m1), PER2 (assay ID: Hs00256143_m1),
TFF3 (assay ID: Hs00902278_m1), and AZGP1 (assay
ID: Hs00426651_m1) was carried out using Taqman
Gene Expression Assays (Applied Biosystems, Mel-
bourne, VIC, Australia) as instructed by the manufac-
turer. Housekeeping gene RPLP0 (Applied Biosystems)
was used as a control. Relative gene expression = gene
expression in the knock-down group or following AR
and MEK inhibition/average gene expression in the con-
trol group. Relative gene expression was calculated
using the 2-ΔΔCT formula as described before [19,20]. All
experiments were performed in at least three biological
replicates.
Western blot analysis
PIP (GCDFP-15) rabbit monoclonal antibody (ab62363)
was obtained from Abcam (Cambridge, UK). Rabbit
monoclonal ERK1/2, rabbit monoclonal phospho-ERK1/2
(Thr202/Tyr204), rabbit monoclonal Akt (pan), rabbit
monoclonal phospho-Akt (Ser473), rabbit monoclonal
CREB, rabbit monoclonal phospho-CREB (Ser133), rabbit
monoclonal ILK1, and rabbit polyclonal ErbB2 antibodies
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were obtained from Cell Signaling (Danvers, MA, USA).
Rabbit polyclonal integrin-b1 antibody was obtained from
Merck Millipore (Melbourne, VIC, Australia).
Western blots were carried out at 1:1000 dilution of
each primary antibody using 10 µg and 20 µg of cell
lysates for the total and phospho-proteins, respectively.
Protein concentrations from the cell isolates were mea-
sured using the BCA Protein Assay Kit (Thermo Scienti-
fic). Rabbit polyclonal a-tubulin antibody (Abcam) was
used as the loading control. Analysis of band densities was
performed using Bio-Profil Densitometer Software (Vilber
Lourmat, Eberhardzel, Germany). All fold changes in band
densities were measured relative to the control groups.
Western blots were performed in two biological replicates
and the average fold change is shown for each set of
experiments.
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed
using EnVision+ System-HRP (AEC), (DakoCytomation,
Melbourne, VIC, Australia) following the manufacturer’s
instructions. Antigen retrieval was carried out using Target
Retrieval Solution (DakoCytomation). AR rabbit polyclonal
and PIP rabbit monoclonal antibodies were obtained from
AbCam. Primary antibody incubations were carried out at
1:100 dilutions. Slides were counterstained with hematoxy-
lin (Sigma-Aldrich) and mounted using Glycergel Mount-
ing Medium (DakoCytomation). For IHC scoring, slides
were examined using a light microscope (Nikon Instru-
ments Inc., Tokyo, Japan). A total of 1,000 cells per each
slide were counted at 60X magnification to assess the per-
centage of cells showing positive staining for each antibody.
Primary breast tumors
The Princess Alexandra Hospital human research ethics
committee approved this study and informed consent was
obtained from each patient for the use of tissue samples.
A total of twenty-four paraffin-embedded ER- breast
tumor samples were obtained from the Princess Alexandra
Hospital tissue bank. IHC staining for AR and PIP were
carried out as described above. For downstream analysis,
tumors were classified into two groups based on their AR
staining pattern as published before [11]: 1) AR+ group
with ≥20% of cells showing positive AR staining, and
2) AR- group with <20% of cells stained for AR.
Tumor xenograft studies
The University of Queensland animal ethics approval was
obtained for the project and mice were maintained in
accordance with the University of Queensland animal
care guidelines. Xenograft studies were carried out as we
previously published [11]. In summary, a total of 5 × 106
MDA-MB-453 cells were injected into the flank of each
six-week-old female non-obese diabetic/severe combined
immunodeficient mouse to generate the xenograft
tumors. Treatments were initiated seven days after the
cell injections.
Flutamide treatment was carried out with 25 mg/60-day
slow-release flutamide pellets (Innovative Research of
America, Sarasota, FL, USA) and MEK inhibition was
carried out with daily oral gavage of MEK inhibitor
PD0325901 (Selleck Chemicals) at 15 mg/kg/day as
described before [11,21]. A total of four mice were studied
in each of the following groups: 1) Control group received
placebo pellets (Innovative Research of America) and daily
oral gavage of an equal volume of carrier solution to that
of the MEK inhibitor treatment group; 2) flutamide group
was treated with the flutamide pellets and daily oral gavage
of carrier solution; and 3) MEK inhibitor group had
placebo pellets and daily oral gavage of PD0325901. Xeno-
graft tumors were harvested 28 days following the start of
treatment in each group. The harvested tumors were fixed
in formalin and embedded in paraffin for IHC staining.
Luciferase reporter assays
Full-length cDNA clones for CREB1 and AR were
obtained from Open Biosystems (Thermo Scientific).
The human prolactin receptor (PRLR) clone was
obtained from GeneCopoeia (Rockville, MD, USA). The
clones were validated by restriction digestion/sequencing
and then sub-cloned in a pcDNA3.1 vector (Invitrogen)
to generate expression constructs. Furthermore, the
sequence of 1.5 kb promoter region of the PIP gene was
obtained using Ensembl Genome Browser [22], and
PCR-generated using the following primers: Forward-
primer, 5’TCTTCTGCCTTATGCCTGCCTTGGT and
Reverse-primer, 5’AAGTGGTGTCCCAGGTGCCCAG.
PIP promoter was then cloned in a pGL3 luciferase
reporter vector (Promega, Sydney, NSW, Australia) and
validated by restriction digestion/sequencing.
To carry out the reporter assays, MCF-7 cells were co-
transfected with the PIP reporter vector and expression
vectors using ExGen 500 reagent (Fermentas Life Sciences,
St Leon-Rot, Germany). The Renilla pRL-TK vector (Pro-
mega) was used as an internal control reporter. Co-trans-
fection with PIP reporter vector and an empty pcDNA
vector was used as a control. Forty-eight hours after the
transfections reporter activities were measured using the
Dual-Glo Luciferase Assay System (Promega) in an Orion
II Microplate Luminometer (Berthold Detection Systems,
Pforzheim, Germany). The response ratios for transcrip-
tion factors and control were measured relative to the
internal control reporter (relative response ratio). Reporter
assay experiments were carried out in phenol red-free (D)
MEM/F12 medium with 10% Charcoal/Dextran treated
serum supplemented with 100 nM of DHT and 5 µg/ml of
ovine prolactin (PRL, Sigma-Aldrich) [11,23]. All reporter
assays were performed in four biological replicates.
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Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were per-
formed in the MDA-MB-453 cell line using a ChIP Assay
Kit (USB Corporation, Cleveland, OH, USA) as instructed
by the manufacturer [24]. ChIP-grade rabbit monoclonal
CREB1 (ChIPAb+ CREB kit, Millipore, Melbourne, VIC,
Australia) antibody was applied at 4 µg per assay. To
quantify ChIP results, two primer sets for PIP promoter
were used for qPCR amplification using the SYBR green
method (Applied Biosystems). Forward primer set 1:
5’AGTGGGGAGGGTGAATGGGTGAT (start: -141) and
Reverse primer set 1: 5’AGTGCAAGAGCTGCCAGGGA-
GAT (start -85), Forward primer set 2: 5’TAAGCCA
GCTCTTTGGTGCCAAG (start: -810) and Reverse
primer set 2: 5’AGATCCCCCAGCTGCCCCACAAT
(start -697). Amplification of input chromatin prior to
immunoprecipitation (IP) at a dilution of 1:100 was used
as a positive control. ChIP assays using non-specific anti-
body (rabbit IgG) served as a negative control. The assays
were carried out in three replicates and percentage recov-
ery of input chromatin was calculated for each experimen-
tal set.
PIP siRNA knockdown
PIP-knockdown was carried out in MDA-MB-453 cells
by reverse transfection as described before [25], using
the following two sets of siRNA oligos (duplex, Sigma-
Aldrich): Set 1: D1, 5’CCUAUGUGACGACAAUCCA;
D2, 5’UGGAUUGUCGUCACAUAGG and set 2: D1,
5’CUCUACAAGGUGCAUUUAA; D2, 5’UUAAAUG-
CACCUUGUAGAG. CREB1-knockdown was carried
out using the following siRNA oligo as described before:
5’GGUGGAAAAUGGACUGGCUtt [26]. Transfection
of siRNA oligos using Lipofectamine RNAiMAX (Invi-
trogen) was carried out as instructed by the manufac-
turer. The final siRNA concentration was 20 nM for the
knock-down experiments. Cells transfected with siRNA
Universal Negative Control # 1 (non-targeting siRNA,
Sigma-Aldrich) were used as controls. In all experiments
the effects of knockdowns were assessed seventy-two
hours after the siRNA transfections.
Cell invasion assay
Cell invasion assays were carried out using CytoSelect
96-Well Cell Invasion Assay Kit (Cell Biolabs Inc., San
Diego, CA, USA) as instructed by the manufacturer. PIP-
siRNA and control-siRNA transfections were carried out
in the MDA-MB-453 cell line as described before. Forty-
eight hours after the siRNA transfections, cells were har-
vested and seeded in an invasion assay plate at 50,000
cells/100 µl per each well. Serum-free L15 medium and
L15 medium with 10% FBS were used for the upper
and lower chambers of the invasion assay plate, respec-
tively. Next, cells were incubated for 24 hours in a 37ºC
incubator before assaying for invasion. Finally, cells were
dissociated from the membrane as per the manufacturer’s
instructions and subsequently detected with CyQuant GR
Fluorescent Dye (Invitrogen). Fluorescence was measured
with a fluorescence plate reader at 480 mm/520 mm.
Treatment with Purified Human Fibronectin (a-Chymo-
tryptic Fragment 120K, Merck Millipore) at 100 µg/ml
concentration was carried out 24 hours after PIP-knock-
down. Invasion assays were carried out in three biological
replicates.
Cell viability assay
PIP-knockdown in MDA-MB-453 cells was carried out as
described before. A total of 10,000 cells transfected with
either PIP-siRNA or control-siRNA were seeded per well
of a 96-well plate. Seventy-two hours after transfections,
cell viability was assessed using the Vybrant 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) Proliferation Assay Kit (Invitrogen) as instructed
by the manufacturer. MTT assays were performed in eight
biological replicates and absorbance at 570 nm was mea-
sured using a plate reader.
Immunoprecipitation
Immunoprecipitation (IP) of integrin-b1 was carried out as
previously published [27]. PIP-knockdown in the MDA-
MB-453 cell line was performed in 6 cm dishes. Seventy-
two hours after siRNA transfections, cells were lysed by
500 µl/per dish of 15 mM CHAPS (Sigma-Aldrich) in lysis
buffer (0.15 M NaCl, 2mM EDTA, 1 mM PMSF, 1 mM
NaVO4, 50 mM Tris-HCl, pH 7.5), then lysates were cen-
trifuged for 20 minutes at 15,000 g. Next, the supernatants
were pre-cleared with Protein A-Sepharose 4B beads (Invi-
trogen) for one hour and protein concentrations from the
cell isolates were measured using the BCA Protein Assay
Kit (Thermo Scientific).
Subsequently, we incubated 300 µg of each protein
lysate with 4 µl of rabbit polyclonal integrin-b1 antibody
(Merck Millipore, Cat. # AB1952) at 4ºC overnight fol-
lowed by incubation with Protein A-Sepharose 4B beads
at 4ºC for four hours. The Sepharose beads were washed
three times with 15 mM CHAPS, then boiled for five min-
utes in SDS-PAGE sample buffer. Finally, samples were
subjected to western blotting as described previously.
Treatment with Purified Human Fibronectin (a-Chymo-
tryptic Fragment 120K) at 100 µg/ml concentration was
carried out 24 hours after PIP-knockdown. IP assays were
performed in two biological replicates and the average fold
change was shown for each set of experiments.
Bioinformatics and statistical analysis
1) Molecular apocrine-genes: Top ranking genes in
molecular apocrine-signature, based on their fold-change
for gene expression, were extracted from a meta-analysis
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microarray study of 186 ER- breast tumors by Teschen-
dorff et al. and an expression microarray study of ER-
cell lines by Doane et al. [4,5]. The combination of the
top eight genes in Teschendorff et al.’s study and the top
six genes in Doane et al.’s study resulted in twelve unique
molecular apocrine genes (Table 1).
2) Promoter analysis: The sequences of the 1.5 kb
promoter region of the PIP gene were obtained using
Ensembl Genome Browser [22]. Identification of puta-
tive CREB1 binding sites in the promoter region was
carried out using PATCH public 1.0 software [28].
3) Bioinformantics and statistical analysis: Heat map
was generated using Spotfire DecisionSite for Functional
Genomics (TIBCO, Somerville, MA, USA). Biostatistical
analysis was carried out using IBM SPSS Statistics 20
(Armonk, NY, USA). The Mann-Whitney U test was
applied for the comparison of non-parametric data. All
error bars depict ± 2SEM.
Results
Molecular apocrine genes are regulated by AR-ERK
signalling
To study the transcriptional regulation of key molecular
apocrine genes by the AR-ERK feedback loop, we first
identified the top ranking genes in the molecular apocrine
signature based on their fold-change for gene expression
as described in methods (Table 1). Among the top twelve
genes in this ranking system, we have previously studied
the transcriptional regulation of AR and ErbB2 in molecu-
lar apocrine breast cancer [10,11]. Therefore, in this study
we investigated the remaining ten genes that are highly
ranked in the molecular apocrine signature (Table 1).
Modulation of the AR-ERK feedback loop in molecular
apocrine cell lines MDA-MB-453 and HCC-1954 was
carried out using AR inhibitor flutamide and MEK inhi-
bitor CI-1040 as we previously published [11,15]. Fluta-
mide treatment was performed at 25 nM and 40 nM
concentrations in MDA-MB-453 and HCC-1954 cell
lines, respectively. These concentrations do not signifi-
cantly inhibit ERK phosphorylation on their own; how-
ever, they have synergy with a low concentration of
CI-1040 at 2 µM to inhibit ERK phosphorylation [11].
Furthermore, CI-1040 was applied at 2 µM and 10 µM,
concentrations that result in a partial or complete inhibi-
tion of ERK phosphorylation, respectively [11]. Both cell
lines were grown to 60% confluence and treated in the
following groups: 1) control with vehicle only treatment,
2) CI-1040 at 2 µM, 3) flutamide treatments at 25 nM or
40 nM, 4) combination of CI-1040 at 2 µM and flutamide
treatments, and 5) CI-1040 at 10 µM concentration.
Forty-eight hours after the treatments, cells were har-
vested for RNA extraction and qPCR as described in
methods.
The fold-changes for gene expression following treat-
ments were calculated relative to that of the control
group in both cell lines. Next, we ranked molecular
apocrine genes based on their fold-change in expres-
sion following the modulation of AR-ERK signaling
(Figure 1A and Table 2). We observed that PIP,
DUSP6, S100A8, and FOXA1 expression were consis-
tently reduced by the inhibition of AR and ERK as well
as the combined inhibition of these two signaling path-
ways in both cell lines (Figure 1A and Table 2). The
other molecular apocrine genes either did not have a
consistent reduction or showed a slight increase in
gene expression following the inhibition of AR and ERK
(Figure 1A and Table 2). It is notable that CI-1040 at
2 µM concentration had markedly less effect compared
to CI-1040 at 10 µM concentration (Table 2). Impor-
tantly, PIP and DUSP6 had the most prominent reduc-
tion in gene expression following the inhibition of
AR-ERK with a fold-change ranging from 0.19 to 0.71
and 0.01 to 0.98, respectively (Figure 1A and Table 2).
However, in contrast to PIP, flutamide treatment did
Table 1 Fold changes of top ranking molecular apocrine-signature genes in two studies.














Naderi and Meyer Breast Cancer Research 2012, 14:R111
http://breast-cancer-research.com/content/14/4/R111
Page 5 of 16
Figure 1 The regulation of molecular apocrine genes by the AR-ERK feedback loop. (A) Heat map of top ranking molecular apocrine-
signature genes following the inhibition of AR-ERK signaling using qPCR data. Heat map shows fold changes for gene expression relative to
control in MDA-MB-453 and HCC-1954 cell lines. Treatments were carried out by CI-1040 (CI) at 2 µM and 10 µM concentrations, flutamide (FLU)
at 25 nM and 40 nM concentrations, and the combination of flutamide at 25 nM or 40 nM and CI-1040 at 2 µM concentrations. Red and green
colors depict up-regulation and down-regulation, respectively. Bar indicates the range of fold changes in gene expression. (B) Box plots to
demonstrate relative expression of PIP to control following AR-ERK inhibition in MDA-MB-453 and HCC-1954 cell lines using qPCR. CTL: control.
(C) Western blot analysis to assess PIP protein levels following AR-ERK inhibition in MDA-MB-453 and HCC-1954 cell lines. Fold changes (RR) in
band densities were measured relative to the control (CTL). AR, androgen receptor; ERK, extracellular signal-regulated kinase; qPCR, quantitative
PCR; RR, relative risk.
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not reduce DUSP6 expression in HCC-1954 cells (fold-
change: 0.98). These data indicate that AR-ERK signal-
ing regulates the transcription of selective molecular
apocrine genes.
PIP expression is highly regulated by AR-ERK signaling
We observed that PIP expression was consistently
reduced following the inhibition of AR-ERK signaling
with a fold-change of 0.19 to 0.71 in MDA-MB-453 cell
line and 0.26 to 0.65 in HCC-1954 line compared to the
control groups (Table 2 and Figure 1B). We next exam-
ined the effect of AR-ERK inhibition on PIP protein
level in MDA-MB-453 and HCC-1954 cell lines. Cells
were harvested forty-eight hours after the treatments
and PIP protein level was measured using western blot
analysis. Notably, PIP protein levels were markedly
reduced following AR-ERK inhibition with a fold-change
of 0.16 to 0.7 and 0.2 to 0.8 compared to the control
groups in MDA-MB-453 and HCC-1954 cell lines,
respectively (Figure 1C). All together, our data suggest
that PIP is significantly regulated by AR and ERK.
Therefore, we investigated the biological significance of
this gene in molecular apocrine breast cancer.
PIP is overexpressed in ER-/AR+ primary breast tumors
We next examined PIP protein expression using IHC in a
cohort of twenty-four ER- breast tumors with known AR
expression status [11]. ER- breast tumors were classified
into AR+ and AR- subgroups as described in the Methods
section and a total of twelve samples (50% of tumors)
showed AR+ staining in this cohort. [11]. We then carried
out IHC staining for PIP and compared the percentage of
positive staining for this protein between AR+ and AR-
samples. AR+ breast tumors showed a markedly higher
expression of PIP (57% ± 6) compared to AR- tumors
(16% ± 4), (P <0.01, Figures 2A and 2B). These findings
suggest that AR+ staining is associated with the overex-
pression of PIP protein in ER- breast tumors.
PIP is regulated in vivo by AR-ERK signaling
To further investigate the regulation of PIP by the AR-
ERK feedback loop, we used an in vivo model of molecular
apocrine breast cancer. Xenograft tumors were generated
using MDA-MB-453 cells as described in methods. A total
of four mice were studied in each of the following groups
for 28 days: 1) control, 2) AR inhibition with flutamide,
and 3) MEK inhibition with PD0325901. We next carried
out IHC staining for PIP in the harvested tumors. Subse-
quently, we determined the percentage of PIP stained cells
and compared the results between each treatment group
and control. We observed that PIP protein expression was
markedly less following flutamide and PD0325901 treat-
ments with 3.5% ± 1 and 4.5% ± 1 of cells expressing PIP,
respectively, compared to that of the control group with
PIP expression in 22% ± 0.06 of cells (P < 0.01, Figures 2C
and 2D). These findings suggest that the in vivo inhibition
of AR and MEK result in a reduction of PIP expression in
molecular apocrine tumors.
PIP is a transcriptional target of CREB1
Since our data suggested that AR and ERK activation are
necessary for PIP expression, we next investigated the reg-
ulation of PIP transcription by AR-ERK signaling. In this
respect, we first examined the activation of PIP promoter
by transcription factors AR and CREB1 using luciferase
reporter assays. CREB1 is a well-characterized down-
stream mediator of ERK signaling that we have previously
shown to be a key transcription factor in regulating mole-
cular apocrine genes AR and FOXA1 [11,20,29,30].
Due to a high degree of transfectability MCF-7 cells
were used for the reporter assay experiments as described
before [11,20,24]. MCF-7 cells were co-transfected with
the PIP reporter vector and each of the PRLR, AR, and
CREB1 expression constructs. Co-transfection with the
PIP reporter vector and an empty pcDNA vector was
used as a control. In addition, to test the effect of PRLR,
Table 2 Fold changes of molecular apocrine-signature genes following treatment with AR and MEK inhibitors.
Tx
Gene
MDA-CI-2 MDA-FLU MDA-FLU-CI MDA-CI-10 HCC-CI-2 HCC-FLU HCC-FLU-CI HCC-CI-10
PIP 0.71 0.63 0.24 0.19 0.65 0.4 0.26 0.42
DUSP6 0.6 0.125 0.01 0.01 0.16 0.98 0.18 0.02
S100A8 1.2 0.09 0.06 0.45 1.3 0.86 0.77 0.68
FOXA1 1.2 0.67 0.5 0.9 1.08 0.71 0.58 0.68
TFAP2 1 0.43 0.15 0.5 1.61 0.53 0.68 1.69
SOX11 1.3 0.56 0.32 0.63 1.97 1 1.95 2.33
BANP 1 0.78 0.9 1 1.16 0.94 1.09 1.07
PER2 1.27 0.85 1.62 1.74 0.93 0.79 0.9 0.59
TFF3 1.71 0.55 0.43 0.73 1.23 1.23 1.72 1.43
AZGP1 1.36 1.29 0.73 1 1.3 1.78 2.23 1.21
* The average fold change to control for three biological replicate experiments is shown for each treatment group. Tx, treatment group; MDA, MDA-MB-453 and
HCC, HCC-1954. FLU, flutamide at 25 µM and 40 µM concentrations for MDA-MB-453 and HCC-1954, respectively. CI-2, CI-1040 at 2 µM and CI-10: CI-1040 at 10
µM. Standard deviation of the fold changes: <0.05.
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Figure 2 PIP protein expression in primary breast tumors and in vivo models. (A) Immunohistochemistry (IHC) staining for PIP in ER
negative (ER-) breast tumors. AR+ group: ≥20% of cells showing positive AR staining; AR- group: <20% of cells stained for AR. Percentage of
cells with positive staining are demonstrated for each group. *P <0.01 is for AR+ versus AR-. Error Bars: ± 2SEM. (B) IHC staining for PIP in AR+
and AR- breast tumors. Magnification is at 60X. (C) IHC staining for PIP in xenograft tumors generated using MDA-MB-453 cell line. Control: a
control tumor; FLU: a flutamide-treated tumor; PD: a PD0325901-treated tumor. Magnification is at 60X. (D) IHC for PIP in xenograft tumors.
Percentage of cells positive for PIP was assessed using IHC and compared between each treatment group and control (CTL). * P <0.01 is for FLU
or PD treatment versus CTL. Error Bars: ± 2SEM. AR, androgen receptor; SEM, standard error of the mean.
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we co-transfected this vector with each of the AR and
CREB1 constructs. Forty-eight hours after the transfec-
tions reporter activities were measured and relative
response ratios were calculated as described in the Meth-
ods section. We observed a significant increase in PIP
reporter activity with CREB1 by approximately two-fold
(P <0.01, Figure 3A). In addition, co-transfection of PRLR
and CREB1 had a similar effect to that of CREB1 alone
(Figure 3A). It is notable that AR vector, with or without
PRLR co-transfection, did not significantly activate PIP
promoter (Figure 3A). These results suggest that CREB1
activates PIP promoter. However, AR does not regulate
the proximal 1.5 kb region of PIP promoter.
We next examined the effect of AR activation by DHT
on PIP expression in MDA-MB-453 and HCC-1954 cell
lines using qPCR. DHT treatments at 100 nM were carried
out at 30 minute, 1 hour, 3 hour, 12 hour, 24 hour, and
48 hour time-points. For each time-point, a control experi-
ment was carried out with cells only treated with the vehi-
cle. Subsequently, fold change in PIP expression was
calculated relative to the respective control at each time-
point. We observed that PIP expression did not increase at
the first 24 hour time-point following DHT treatments
(Figure 3B). However, PIP expression incrementally
increased at the 24 hour and 48 hour time-points, particu-
larly in the MDA-MB-453 cell line (P <0.03, Figure 3B).
These findings indicate that DHT treatment has a delayed
effect on the induction of PIP expression in molecular
apocrine cells.
Examination of the 1.5 kb PIP promoter region identified
several putative binding sites for CREB1 (Figure 3C). In
view of this and to assess the binding of CREB1 to the PIP
promoter we carried out ChIP assays in the MDA-MB-453
cell line. Two sets of primers for the PIP promoter in
proximity to the predicted binding sites were used for
qPCR amplification as described in the Methods section
(Figure 3C). The percentage recovery of input chromatin
was calculated for each experimental set (Figure 3D).
Importantly, we observed a significant enrichment for the
PIP promoter region with CREB1 antibody using both pri-
mer sets (P <0.01, Figure 3D). Finally, we measured PIP
protein expression following CREB1-knockdown in MDA-
MB-453 cells. We observed that the CREB1 protein level
was reduced by 90% following siRNA transfection and this
resulted in an approximately 70% reduction of PIP protein
expression (Figure 3E). All together, these data suggest that
PIP is a target gene of CREB1 and the activation of AR has
a delayed effect in the induction of PIP expression in mole-
cular apocrine cells.
PIP is necessary for cell invasion and viability
PIP is an aspartic-type protease with a specific fibronec-
tin-degrading ability [31]. Although it is known that PIP
is expressed in primary and metastatic breast cancers, the
function of this protein in molecular pathogenesis of
breast carcinoma remains largely unknown [32]. In order
to investigate the biological significance of PIP in mole-
cular apocrine cancer, we studied the functional effects
of PIP on cell invasion and viability using the MDA-MB-
453 cell line. The MDA-MB-453 line was used for the
functional experiments since it represents a widely
accepted cell line model for molecular apocrine subtype
[5,10-12,33].
To test the functional effects of PIP we carried out PIP-
knockdown in MDA-MB-453 cells using two siRNA
duplexes as described in the Methods section. The effi-
ciency of knockdowns was assessed by qPCR and western
blot analysis. Importantly, we observed an approximately
90% reduction in PIP transcription and 80% reduction in
PIP protein level following PIP-knockdown with both
siRNA duplexes (Figures 4A and 4B).
We first examined whether PIP expression is required
for cell invasion in molecular apocrine cells. Cell invasion
was assessed using a basement membrane, fluorometric
cell invasion assay kit as described in the Methods sec-
tion. Invasion assays were carried out in three biological
replicates for each of the following groups: 1) control-
siRNA, 2) PIP-siRNA duplex1 (PIP-D1), and 3) PIP-
siRNA duplex2 (PIP-D2). Subsequently, fluorescence
measurements at 480 mm/520 mm were compared
between PIP-knockdown and control groups. Notably,
there was a marked reduction in cell invasion by approxi-
mately three-fold following PIP-knockdown with
both duplexes compared to the control group (P <0.03,
Figure 4C). We next assessed the effect of PIP expression
on cell viability. MDA-MB-453 cells were studied in PIP-
D1, PIP-D2, and control-siRNA groups and cell viability
was assessed using MTT assay seventy-two hours after
siRNA transfections. We observed a 30% to 40% reduc-
tion in cell viability following PIP-knockdown compared
to the control group (P <0.03, Figure 4D). These findings
suggest that PIP expression is necessary for cell invasion
and viability in molecular apocrine cells.
PIP is necessary for the activation of ERK and Akt signaling
To investigate an underlying mechanism for the effect of
PIP on cell viability, we examined the signaling conse-
quences of PIP-knockdown in molecular apocrine cells.
PIP-knockdown was carried out using PIP-D1 and PIP-D2
in the MDA-MB-453 cell line and non-targeting siRNA
was used as a control. Seventy-two hours after transfec-
tions protein lysates were extracted for western blot analy-
sis. We first studied the effect of PIP-knockdown on the
phosphorylation of ERK and Akt, since these phosphoryla-
tions are key signaling events in cell proliferation [34].
Following western blot analysis, fold changes in phos-
pho-ERK/total-ERK and phospho-Akt/total-Akt ratios
were measured in PIP-knockdown relative to the control.
Notably, there was a marked reduction in phospho-ERK/
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Figure 3 Transcriptional regulation of PIP by AR and CREB1. (A) Luciferase reporter assay. The transcriptional activation of PIP promoter by
PRLR, AR, CREB1, PRLR + AR, and PRLR + CREB1 expression constructs was assessed using Dual-Luciferase assays in MCF-7 cells and relative
response ratios are reported. Co-transfection with the PIP reporter vector and an empty pcDNA vector was used as a control (CTL). *P <0.01, is
compared to the control group. (B) Induction of PIP expression following DHT treatment. PIP expression was assessed using qPCR following DHT
treatment at 30 minute, 1 hour, 3 hour, 12 hour, 24 hour, and 48 hour time-points in MDA-MB-453 and HCC-1954 cell lines. Fold changes are
measured relative to the respective control at each time point. *P <0.03, is compared to the control group (dashed line). Error Bars: ± 2SEM. (C)
Putative transcription factor binding sites for CREB1 in 1.5 kb promoter region of PIP. P1 (primer set 1) and P2 (primer set 2) are regions of
amplification for ChIP assays. (D) ChIP assay with CREB1 antibody. The results of qPCR amplification for ChIP assays are demonstrated with two
sets of primers for PIP promoter. Percentage recovery of input chromatin is shown for each primer set. *, P <0.01 is for CREB1 Ab. versus control
Ab. Error Bars: ± 2SEM. (E) Western blot analysis to show CREB1 and PIP protein levels following CREB1-knockdown using siRNA in MDA-MB-453
cell line. Fold changes (RR) in band densities were measured relative to non-targeting siRNA control (CTL). Ab, antibody; AR, androgen receptor;
ChIP, chromatin immunoprecipitation; DHT, dihydrotestosterone; qPCR, quantitative PCR; RR, relative risk; SEM, standard error of the mean.
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total-ERK ratio between 0.2- and 0.5-fold following PIP-
knockdown (Figure 5A). Similarly, PIP-knockdown resulted
in a 0.4- to 0.7-fold reduction of phospho-Akt/total-Akt
ratio (Figure 5A). We next assessed the effect of PIP-
knockdown on the phosphorylation of CREB1. CREB1 is a
critical downstream mediator of the EGFR-ErbB2 pathway,
which is activated by both Akt and ERK signaling
[29,35,36]. Fold change in phospho-CREB1/total-CREB1
ratio was measured in PIP-knockdown relative to the con-
trol. Consistent with phospho-ERK and phospho-Akt data,
we observed a marked reduction in phospho-CREB1/total-
CREB1 ratio between 0.2- and 0.4-fold following PIP-
knockdown (Figure 5B). These findings suggest that PIP
expression is necessary to maintain the phosphorylation of
ERK, Akt, and their downstream target CREB1 in molecu-
lar apocrine cells.
PIP is necessary for integrin-b1 binding to ILK1 and ErbB2
Enzymatic degradation of fibronectin releases fragments
that bind to integrin-b1 and activate intracellular signal-
ing by its cytoplasmic tail [37,38]. It is known that the
activation of integrin-b1 promotes cell adhesion and
invasion [37,39]. In addition, integrin-b1 activation
induces some of the key signaling pathways such as
MAPK/ERK and PI3K/Akt that are involved in cell prolif-
eration [37,40]. Since it is known that PIP is a protease
with fibronectin-degrading ability [31], we hypothesized
that PIP may be required for the integrin-b1 activation in
molecular apocrine cells.
Integrin-b1 activation by fibronectin fragments leads
to the binding of this receptor to its binding partners.
One of the integrin-b1 key binding partners is integrin-
linked kinase 1 (ILK1), which binds to the activated
Figure 4 The effect of PIP knockdown on cell invasion and viability. (A) qPCR to demonstrate PIP-knockdown efficiencies with siRNA-
duplex1 (D1) and siRNA-duplex2 (D2) in MDA-MB-453 cell line. PIP expression following knockdown was assessed relative to non-targeting siRNA
control (CTL) and fold change is shown for each duplex. (B) Western blot analysis to show PIP protein level following PIP-knockdown in MDA-
MB-453 cell line as described in (A). Fold changes (RR) in band densities were measured relative to the control (CTL). (C) The effect of PIP
expression on cell invasion. Cell invasion assays were carried out after PIP-knockdown with PIP-D1 and PIP-D2 in MDA-MB-453 cell line.
Transfection with non-targeting siRNA control (CTL) was used as a control. *, P <0.03 is for each PIP-knockdown versus CTL. Error Bars: ± 2SEM.
(D) MTT assay to measure cell viability following PIP-knockdown with PIP-D1 and PIP-D2 in MDA-MB-453 cell line. CTL: non-targeting siRNA
control. *, P <0.03 is for each PIP-knockdown versus CTL. Error Bars: ± 2SEM. MTT, 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
qPCR, quantitative PCR; RR, relative risk; SEM, standard error of the mean.
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Figure 5 The effect of PIP knockdown on ERK-Akt and integrin-b1signaling. (A) Western blot analysis to measure the levels of
phosphorylated (Ph)-ERK, total (T)-ERK, ph-Akt, and T-Akt following PIP-knockdown with siRNA duplex1 (PIP-D1) and duplex2 (PIP-D2) in MDA-
MB-453 cell line. Fold changes of Phospho/Total ratios (Ph/T-RR) were assessed relative to non-targeting siRNA control (CTL). (B) Western blot
analysis to measure the level of ph-CREB1, T-CREB1, and ILK1 following PIP-knockdown as described in (A). Ph-ATF1 is the phosphorylated form
of CREB-related protein that is known to be detected by this antibody. (C) Integrin-b1 immunoprecipitation (IP). IP assays were carried out with
Integrin-b1 following PIP-knockdown with PIP-D1 and PIP-D2 in MDA-MB-453 cell line. Non-targeting siRNA was used as control (CTL). Western
blot analysis was carried out on IP samples to measure the integrin-b1 binding to ILK1 and ErbB2. Immunoblotting with integrin-b1 antibody
was used as a loading control. Fold changes (RR) of ILK1 and ErbB2 following PIP-knockdown were measured relative to that of control-siRNA.
(D) Integrin-b1 immunoprecipitation following PIP-knockdown and the addition of fibronectin fragments (Fn-fs). PIP-knockdown with PIP-D1 was
carried out as described in (C). Twenty-four hours after PIP-knockdown, cells were treated with a-chymotryptic fibronectin fragment 120K at 100
µg/ml concentration. Control cells were treated with vehicle only. Fold changes (RR) of ILK1 and ErbB2 following PIP-knockdown + Fn-fs were
measured relative to the control. (E) The effect of fibronectin fragments on cell invasion following PIP-knockdown. Cell invasion assays were
carried out after PIP-knockdown with PIP-D1 in MDA-MB-453 cell line. Transfection with non-targeting siRNA control (CTL) was used as a control.
Treatment with fibronectin fragments was carried out as described in (D). Error Bars: ± 2SEM. Δ; is the difference between CTL and PIP-D1+Fn-fs
groups. ERK, extracellular signal-regulated kinase; ILK1, integrin-linked kinase 1; RR, relative risk; SEM, standard error of the mean.
Naderi and Meyer Breast Cancer Research 2012, 14:R111
http://breast-cancer-research.com/content/14/4/R111
Page 12 of 16
integrin-b1 and mediates downstream signaling effects
such as the activation of Akt [41,42]. Therefore, we
investigated the effect of PIP-knockdown on the binding
between integrin-b1 and ILK1 using an IP assay. Trans-
fections of PIP-D1 and PIP-D2 were carried out in the
MDA-MB-453 cell line and non-targeting siRNA was
used as a control. Seventy-two hours after siRNA trans-
fections, cells were lysed for IP and immunoblotting
assays. It is notable that ILK1 protein levels were similar
in the extracted lysates among PIP-knockdown and con-
trol experiments (Figure 5B). We next carried out an IP
assay with integrin-b1 antibody and subjected the sam-
ples to western blot analysis using ILK1 antibody.
Immunoblotting of IP samples using integrin-b1 anti-
body was used as a loading control. Importantly, there
was a 70% to 90% reduction in binding of integrin-b1 to
ILK1 following PIP-knockdown compared to the control
(Figure 5C).
Moreover, it has previously been reported that integrin-
b1 binds to ErbB2 in human carcinoma cell lines [43].
Since ErbB2 overexpression is present in the majority of
molecular apocrine tumors, we examined the association
between integrin-b1 and ErbB2 in MDA-MB-453 cells and
evaluated a possible role for PIP expression in this process.
Following IP assays in PIP-knockdown and control-siRNA
samples, we carried out western blot analysis using ErbB2
antibody. Notably, we observed that integrin-b1 binds to
ErbB2 in the control experiment and this binding was
decreased by 90% following PIP-knockdown compared to
the control (Figure 5C).
Finally, we asked whether the effects of PIP-knock-
down in the reduction of integrin-b1 binding to ILK1
and ErbB2 can be reversed by fibronectin fragments.
This was assessed by the addition of a-chymotryptic
fibronectin fragment 120K at 100 µg/ml concentration
24 hours after transfection of MDA-MB-453 cells with
PIP-D1. Transfection with non-targeting siRNA and
treatment with vehicle only was used as a control. Fol-
lowing the extraction of lysates and IP assays we sub-
jected the samples to western blotting using ILK-1 and
ErbB2 antibodies. Immunoblotting with integrin-b1 anti-
body was applied as a loading control. Importantly, we
observed a nearly complete recovery of integrin-b1
binding to ILK1 and ErbB2 in PIP-knockdown experi-
ments following the addition of fibronectin fragments to
levels similar to that of the control (Figure 5D). More-
over, the addition of fibronectin fragments reversed the
reduction of cell invasion observed following PIP-knock-
down to approximately 80% of the control levels (Figure
5E). All together, these data suggest that PIP expression
is necessary for integrin-b1 binding to ILK1 and ErbB2
in a process that is mediated through the fragmentation
of fibronectin.
Discussion
Molecular apocrine is one of the major subtypes of ER-
breast cancer that is characterized by the overexpression
of a steroid-response gene signature [3-5]. Investigation
of key functional pathways in this subtype of breast can-
cer is an essential step for the discovery of effective thera-
peutic strategies in this disease. We have recently
identified a positive feedback loop between the AR and
ERK signaling pathways in the molecular apocrine sub-
type that is mediated through ErbB2 and CREB1 [11]. In
this study, we demonstrated that this AR-ERK feedback
loop regulates the transcription of some of the top rank-
ing genes in the molecular apocrine signature (Figure 1A
and Table 2). Among these genes, we observed that PIP,
DUSP6, S100A8, and FOXA1 expression were consis-
tently reduced following the inhibition of AR-ERK
signaling.
DUSP6 is a specific ERK phosphatase that is highly
regulated by ERK at the promoter level mediated
through ETS1, a well known target of activated ERK
[44]. This phenomenon explains the significant reduc-
tion of DUSP6 expression following the inhibition of
AR-ERK signaling. In addition, the presence of DUSP6,
a gene closely regulated by ERK signaling, among the
top ranking genes in the molecular apocrine signature
provides further support for the importance of ERK acti-
vation in this subtype of breast cancer. FOXA1 is
another highly regulated gene by AR-ERK signaling that
has been the subject of intense interest because of its
emerging role as a critical modulator of ER and AR
function [33,45,46]. In addition, we have recently identi-
fied a cross-regulation network between FOXA1 and
ErbB2 signaling that connects FOXA1 to some of the
key signaling pathways in ER- breast cancer [20]. More-
over, we observed that S100A8 expression is regulated
by the modulation of AR-ERK. S100A8 and its isoform
S100A9 form a secreted protein complex that is
involved in inflammation, cell invasion and migration
[47]. The observed regulation of S100A8 by AR-ERK
signaling is in agreement with a previous study that
demonstrated a positive feedback loop between Ras-
activated ERK and S100A8 expression [48]. Importantly,
in our study PIP was the most regulated molecular
apocrine gene by AR-ERK signaling and, therefore, we
investigated the biological significance of this gene in
the molecular apocrine subtype.
PIP is a secreted protein with aspartic-type protease
activity specific to fibronectin [31]. Several studies have
shown that PIP protein is overexpressed in primary and
metastatic breast cancers with a possible prognostic value
in this disease [32,49-51]. Despite these findings, the func-
tional role of PIP in breast cancer has remained largely
unknown. Our findings suggest that PIP is overexpressed
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in ER-/AR+ breast tumors and PIP expression is highly
regulated by AR-ERK signaling in both in vitro and in vivo
molecular apocrine models (Figures 1 and 2). Considering
that the majority of molecular apocrine tumors have lumi-
nal features [52], the PIP expression pattern in ER- breast
tumors may contribute to the biological differences
observed between the luminal and basal subtypes of ER-
breast cancer. It is notable that PIP protein expression has
been associated with apocrine histological differentiation
[49], and, therefore, the overexpression of PIP represents a
common feature between molecular apocrine subtype and
apocrine histological classification.
The regulation of PIP expression by the AR-ERK feed-
back loop is explained by the fact that PIP is a CREB1 tar-
get gene and is induced by AR activation (Figure 3).
CREB1 is a well-characterized ERK signaling transcription
factor that is a down-stream target of active ERK through
the mediation of the RSK and MSK family of kinases
[29,30,35,53,54]. Importantly, AR itself is a CREB1 target
gene that activates the ERK-CREB1 axis through the
induction of ErbB2 expression [11]. Therefore, the tran-
scriptional regulation of PIP is mediated by a positive feed-
back loop between AR and CREB1 in molecular apocrine
cells. Furthermore, we have recently demonstrated that
the molecular apocrine gene FOXA1 is also a CREB1 tar-
get gene [11,20]. All together, these findings suggest that
the ERK-CREB1 axis has a key role in the transcriptional
regulation of the molecular apocrine genes.
Moreover, transcriptional regulation of PIP by AR has
been previously studied [55-57]. In general, hormonal reg-
ulation of PIP expression is a complex process that
involves gene structure differences and tissue-specific
transacting factors [32]. For example in ER+ cell lines,
STAT5 and Runx2 cooperate with AR to stimulate PIP
transcription [56,57]. Our results suggest that AR does not
directly activate the proximal 1.5 kb region of the PIP pro-
moter. However, it is possible that AR activation of PIP
can be mediated through a more distant site. In fact, it has
recently been shown that Runx2 and AR co-regulate an
enhancer site 11 kb upstream of the PIP transcription
start site [57]. Moreover, we observed a delayed pattern of
PIP induction in molecular apocrine cells following the
activation of AR by DHT starting at the 24 hour time-
point (Figure 3B). This represents a different pattern of
induction compared to that observed with some of the
other AR-activated genes, such as PSA and ErbB2, that
demonstrate a rapid increase in expression within
12 hours of DHT treatment [11,58]. It is notable that a
delayed induction of PIP following DHT has been pre-
viously reported in other studies [59], and may indicate
the time necessary for the activation of other signaling
pathways needed in the stimulation of PIP transcription.
Our study suggests that there is a feedback loop between
PIP and ERK-Akt signaling in molecular apocrine cells
(Figure 6). Following the induction of PIP expression by
CREB1, the secreted PIP mediates protease degradation of
fibronectin to fragments, which results in the activation of
integrin-b1 signaling (Figures 5 and 6). Importantly, in the
absence of PIP there is a marked reduction of integrin-b1
binding to its binding partners ILK1 and ErbB2 that
can be reversed by the addition of fibronectin fragments
(Figures 5C and 5D). ILK1 is a key binding partner of the
activated integrin-b1 receptor that mediates the induction
of Akt and ERK signaling pathways [41,42,60]. In addition,
integrin-b1 is associated with the EGFR-ErbB2 receptor
family and mediates an EGF-independent activation of the
EGFR-ErbB2 signaling pathway, which in turn results in
the induction of MAPK/ERK signaling and cell prolifera-
tion [27,43,61]. In fact, we observed a marked reduction in
the phosphorylation levels of ERK, Akt, and their down-
stream target CREB1 following PIP-knockdown in mole-
cular apocrine cells (Figures 5A and 5B). Since PIP is a
CREB1 target gene, this regulation of CREB1 phosphoryla-
tion by PIP provides a positive feedback loop mechanism
between PIP and CREB1 mediated through the integrin-
ERK and integrin-Akt signaling pathways (Figure 6).
The functional significance of PIP is evident by the fact
that PIP expression is necessary for cell invasion and viabi-
lity in molecular apocrine cells (Figure 4). Notably, a
three-fold reduction in cell invasion observed following
PIP-knockdown indicates that the secretion of this protein
has a key role in maintaining the invasive properties of
molecular apocrine cells. These functional effects can be
explained by the positive regulatory role of PIP on the
integrin-ERK and integrin-Akt signaling pathways
mediated through the generation of fibronectin fragments
(Figure 6). Interestingly, secretion of other fibronectin-
degrading enzymes such as neutral serine proteases have
been reported in T-cell lymphomas [62], suggesting that a
similar process may be involved in the invasion of other
malignant cells. Furthermore, our findings regarding the
effect of PIP expression on cell viability is consistent with
a recent study that demonstrated a decrease in the prolif-
eration of the ER+ cell line T47D following PIP down-reg-
ulation [57].
Conclusions
In summary, we have characterized the PIP signaling path-
way in molecular apocrine breast cancer (Figure 6). We
demonstrated that PIP expression is necessary for the acti-
vation of integrin-b1 signaling and the induction of the
ERK and Akt signaling pathways as well as their down-
stream target CREB1. Furthermore, we showed that PIP is
a CREB1 target gene and, therefore, there is positive feed-
back loop between PIP and CREB1 signaling.
Importantly, PIP expression has a profound effect in
maintaining cell invasion and viability of molecular apoc-
rine cells. These findings offer the tantalizing possibility
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of exploiting PIP signaling as a potential therapeutic tar-
get in molecular apocrine breast cancer.
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